Recently diagnosed with HIV? Click here

Dolutegravir

572.gif

A dose-finding study of dolutegravir (GSK 572), has found that 50mg a day compares well with efavirenz (both combined with emtricitabine/tenofovir).

People seemed to tolerate it well and it had an impressive virological success rate, almost 90% by the end of follow up. There were some slight increases in creatinine levels in the dolutegravir armAny of the treatment groups in a randomised trial. Most randomised trials have two "arms," but some have three "arms," or even more.. (Increased creatinine is linked to kidney problems.)

Phase IIIA large clinical trial designed to establish whether a drug is effective and safe enough for widespread use. Phase III studies include expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling. trials are currently ongoing for this very interesting potent, once-a-day compound.

Generic name: Dolutegravir (572)
Brand name:Vivicay
Also known as:GSK1349572
Drug class:integrase inhibitor
Availability in Australia:
  • Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers.
  • This drug may be available through clinical trials in Australia.
Links:

Like most anti-HIV drugs, Dolutegravir must be taken in combination with other drugs to be completely effective. Your doctor will advise you on the right combination of drugs to suit your circumstances.

Side effects

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

    The integrase inhibitor

    Positive Living article • Jae Condon • 28 February 2014

    Last spring, Positive Living began a series on the different HIV treatments and how they are grouped by class according to the stage of the HIV life cycle that they block. read more »

    Spotlight on Seattle

    Positive Living article • Adrian Ogier • 7 June 2012

    The 19th Conference on Retroviruses and Opportunistic Infections (Croi) was held in Seattle in march. Here are some important highlights. read more »

    New treatment briefs

    Positive Living article • Adrian Ogier • 1 September 2011

    Adrian Ogier gives the low-down on latest antiretroviralA medication or other substance which is active against retroviruses such as HIV. treatments. read more »

    Report from Rome - 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention

    Story • www.i-base.info • 28 July 2011

    The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention was held in Rome last week from 17-20 July. This meeting is held every two years and alternates with the much larger World AIDS Conferences also organised by the International AIDS Society (IAS). read more »

    The buzz from Boston

    Positive Living article • Neil McKellar-Stewart • 26 May 2011

    The Conference on Retroviruses and Opportunistic Infections reports important advances in HIV treatments and clinicalPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science. care. The 18th CROI was held in Boston in March. Neil McKellar-Stewart highlights some of the good bits. read more »

    Once-daily raltegravir not as effective

    Positive Living article • Adrian Ogier • 25 February 2011
    Treating HIV

    Merck has terminated a trial comparing once-daily dosing against the currently recommended twice-daily dosing of raltegravir. read more »

    Raltegravir approved for first line

    Positive Living article • Adrian Ogier • 3 September 2010
    Treating HIV

    The Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) has broadened access to raltegravir (Isentress) beyond treatment-experienced adults.

    Raltegravir is now also available for people who are first starting HIV treatment.

    Raltegravir + Truvada is now one of four preferred commencing regimens in the Australian HIV Treatment Guidelines. read more »

    News from IAS 2010

    Positive Living article • Adrian Ogier • 2 September 2010

    Adrian Ogier gives a round up of treatments news from the Vienna Conference. read more »

    Treatments news from the IAS Conference

    Positive Living article • 20 August 2009
    pregnancy and childbirth

    A roundup of HIV treatments developments from the IAS Conference in Cape Town. read more »

    Treatment news from CROI

    Positive Living article • John Daye • 13 March 2009

    John Daye reports on treatments developments from the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montréal, Canada. read more »

    The table below shows all the clinical trials in the database with the keyword integrase inhibitors.

    Short titleStatus
    Single No longer enrolling
    SPRING 2 No longer enrolling
    SAILING Concluded
    Syndicate content
    Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

    This Treatments database entry was first published on 17 March 2011 — more than three years ago.

    While the content of this treatments database entry was checked for accuracy at the time of publication, NAPWHA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

    This article may contain medical information. NAPWHA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

    The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

    Website links